Wixela Inhub Powder
Product Images NDC 63629-4989

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Wixela Inhub (NDC 63629-4989). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Instructions For Use Figure A (Image 01)

Instructions For Use Figure A (Image 01)
FDA Label Image

Fluticasone Propionate Structural Formula (Image 02)

Fluticasone Propionate Structural Formula (Image 02)
FDA Label Image

Salmeterol Zinofoate Structural Formula (Image 03)

Salmeterol Zinofoate Structural Formula (Image 03)
FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 04)

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 04)
Not available*
FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 05)

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 05)
This text provides data on the change in Forced Expiratory Volume (% Change in FEV) for the first treatment day involving various medications such as Fluticasone propionate and Salmeterol. The study includes a placebo group as well. It shows the baseline values for comparison.*
FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 06)

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 06)
FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Image 07)

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Image 07)
FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Image 08)

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Image 08)
FDA Label Image

Instructions For Use Figure B (Image 09)

Instructions For Use Figure B (Image 09)
FDA Label Image

Instructions For Use Figure C (Image 10)

Instructions For Use Figure C (Image 10)
FDA Label Image

Instructions For Use Figure D (Image 11)

Instructions For Use Figure D (Image 11)
FDA Label Image

Instructions For Use Figures E And F (Image 12)

Instructions For Use Figures E And F (Image 12)
FDA Label Image

Instructions For Use Figure G (Image 13)

Instructions For Use Figure G (Image 13)
FDA Label Image

Instructions For Use Figure H (Image 14)

Instructions For Use Figure H (Image 14)
FDA Label Image

Instructions For Use Refill Image 01 (Image 15)

Instructions For Use Refill Image 01 (Image 15)
FDA Label Image

Instructions For Use Refill Image 02 (Image 16)

Instructions For Use Refill Image 02 (Image 16)
FDA Label Image

Instructions For Use Refill Image 03 (Image 17)

Instructions For Use Refill Image 03 (Image 17)
FDA Label Image

Label (Lbl636294989)

Label (Lbl636294989)
The text describes a medication containing 250 mcg of Fluticasone Propionate and 72.5 mcg of Salmeterol Xinafoate, equivalent to 50 mcg of Salmeterol base. The medication is in inhalation powder form and each dose is delivered with an INHUB device. It provides instructions on storage conditions, expiration period, and dosage guidance. It is essential to follow the doctor's directions, store the medication in a cool, dry place, and away from direct heat or sunlight. It also advises keeping the medication out of reach of children and provides a QR code for scanning to access additional information.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.